ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Allenby Capital Limited ('Allenby') as joint corporate broker, with immediate effect to work alongside the Company's existing nominated adviser and joint broker, Stifel Nicolaus Europe Limited.

Michael Hunt, Chief Financial Officer of ReNeuron, commented: 'The Company is pleased to appoint Allenby as its joint corporate broker, which, together with the appointment of Walbrook PR as the Company's new investor relations and PR adviser, will further broaden our investor outreach activities, particularly with regards to private client brokers and retail investors.'

Contact:

Olav Hellebo

Tel: +44 (0)20 3328 5656

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.

(C) 2021 Electronic News Publishing, source ENP Newswire